BAYRY News and Press, Bayer AG ADR

2024-06-14 12:58:31 ET More on Ocular Therapeutix Ocular Therapeutix: Betting On Axpaxli For A Major Market Breakthrough Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results Ocular Therapeutix's Impressive Surge: A Strategic Insight ...

2024-06-08 10:19:36 ET More on AstraZeneca, Bristol-Myers, etc. Merck & Co., Inc. (MRK) Investor Event at ASCO 2024 (Transcript) Bristol-Myers: Why I Am Buying More Of This Falling Knife, Yielding 5.84% Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly ...

2024-06-05 07:00:07 ET Summary Bayer's Roundup verdict reduced to $400M in damages by Pennsylvania judge. United Airlines expected to cut hiring plans. Nike cuts jobs at its European headquarters as part of a cost-cutting plan. Listen below or on the go on Apple Po...

2024-06-04 19:19:54 ET More on Bayer Bayer: Small Signs Of Improvement Are Not Enough Bayer Q1 2024 Earnings Call Transcript Bayer Q1 2024 Results - Earnings Call Presentation Read the full article on Seeking Alpha For further details see: Bayer's...

2024-06-04 10:26:59 ET More on Bristol-Myers Squibb Company Bristol-Myers: Why I Am Buying More Of This Falling Knife, Yielding 5.84% Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be...

2024-06-03 14:01:03 ET More on Gilead Sciences, Arcus Biosciences Gilead Sciences: Seriously Undervalued At Peak Pessimism Gilead Sciences: Disappointing Fundamentals And Sentiment, But Still Bullish Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO ...

2024-06-02 03:00:00 ET Summary Suzhou MediLink partners with BioNTech to use its antibody-drug conjugate platform, receiving an upfront payment of $25 million and up to $1.8 billion in milestones. Asahi Kasei offers $1.1 billion to acquire Calliditas Therapeutics, aiming to expand...

2024-05-30 05:05:01 ET More on Burning Rock Biotech, Bayer: Read the full article on Seeking Alpha For further details see: Burning Rock Biotech joins hands with Bayer to expand precision cancer therapies portfolio

2024-05-29 17:44:01 ET Summary ESSA Pharma Inc. is developing Masofaniten, a drug that disrupts the androgen receptor to stop prostate cancer growth, with promising results in phase 1 trials. Masofaniten has the potential to overcome resistance to other standard-of-care treatments...

2024-05-25 11:00:00 ET Summary Harris Associates is an asset management firm that serves as the investment adviser to the Oakmark Funds. We seek to invest in businesses that are priced at substantial discounts to our estimate of intrinsic value. Major global equity markets showed ...